Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 5.56% and Operating profit at 7.99% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 16.05% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 5.56% and Operating profit at 7.99% over the last 5 years
3
Negative results in Mar 26
4
With ROE of 10.88%, it has a fair valuation with a 1.13 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,626 Million (Mid Cap)
9.00
NA
3.18%
0.79
10.88%
1.04
Revenue and Profits:
Net Sales:
8,558 Million
(Quarterly Results - Jun 2026)
Net Profit:
140 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.96%
0%
3.96%
6 Months
-9.02%
0%
-9.02%
1 Year
-9.27%
0%
-9.27%
2 Years
10.52%
0%
10.52%
3 Years
-17.38%
0%
-17.38%
4 Years
-1.38%
0%
-1.38%
5 Years
-18.2%
0%
-18.2%
Zhejiang Int'l Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.56%
EBIT Growth (5y)
7.99%
EBIT to Interest (avg)
5.18
Debt to EBITDA (avg)
3.95
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
3.40
Tax Ratio
25.05%
Dividend Payout Ratio
36.88%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.58%
ROE (avg)
16.05%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.94
EV to EBIT
10.36
EV to EBITDA
8.67
EV to Capital Employed
0.97
EV to Sales
0.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.34%
ROE (Latest)
10.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
8,557.70
8,595.00
-0.43%
Operating Profit (PBDIT) excl Other Income
284.40
216.00
31.67%
Interest
30.80
26.70
15.36%
Exceptional Items
0.00
0.00
Consolidate Net Profit
140.00
103.20
35.66%
Operating Profit Margin (Excl OI)
25.70%
17.60%
0.81%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -0.43% vs -1.40% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 35.66% vs -53.74% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
33,634.70
33,312.90
0.97%
Operating Profit (PBDIT) excl Other Income
1,182.30
1,124.60
5.13%
Interest
168.00
155.30
8.18%
Exceptional Items
0.50
0.10
400.00%
Consolidate Net Profit
604.00
611.90
-1.29%
Operating Profit Margin (Excl OI)
28.20%
27.70%
0.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.97% vs 4.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -1.29% vs 3.94% in Dec 2024
About Zhejiang Int'l Group Co., Ltd. 
Zhejiang Int'l Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






